We Think Some Shareholders May Hesitate To Increase Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO Compensation [Yahoo! Finance]
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: Yahoo! Finance
Total compensation is 99% above industry average Akoya Biosciences' three-year loss to shareholders was 89% while its EPS grew by 56% over the past three years The underwhelming share price performance of Akoya Biosciences, Inc. NASDAQ:AKYA ) in the past three years would have disappointed many shareholders. What is concerning is that despite positive EPS growth, the share price has not tracked the trend in fundamentals. The AGM coming up on the 4th of June could be an opportunity for shareholders to bring these concerns to the board's attention. They could also try to influence management and firm direction through voting on resolutions such as executive remuneration and other company matters. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment. See our latest analysis for Akoya Biosciences How Does Total Compensation For Brian McKelligon Compare With Other Companies In The Industry? According to our data, Ako
Show less
Read more
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- Akoya Biosciences Second Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]Yahoo! Finance
- Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.MarketBeat
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Craig Hallum from $7.50 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
AKYA
Earnings
- 8/5/24 - Miss
AKYA
Sec Filings
- 9/3/24 - Form 4
- 9/3/24 - Form 3
- 8/28/24 - Form SC
- AKYA's page on the SEC website